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Inflammatory Disease
(5) The Medical Treatment of Inflammatory Bowel Disease―Up to Date―
Teppei Omori
Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan
Inflammatory bowel disease (IBD) is defined as ulcerative colitis (UC) and Crohn’s disease (CD). The number of
patients with IBD is continuously increasing, with over 200,000 cases of UC and 70,000 cases of CD observed in a
2014 statistical analysis. The mechanisms underlying IBD inflammation remain unclear; however, previous stud-
ies have reported that a genetic predisposition to the disease exists. These disease-susceptibility genes, changes
in the gut microbiota, and an overreaction to dietary antigens are presumed to cause an uncontrolled immune re-
sponse, leading to intestinal inflammation. Therefore, drugs for the treatment of IBD are classical anti-
inflammatory agents, and presently, new immunological drugs, that have been developed from the perspective of
treating IBD, are used in clinical practice. The Japanese Ministry of Health, Labour and Welfare (MHLW) have
developed guidelines for the treatment of IBD in Japan. Appropriate treatment for IBD may vary depending on
the activity, extent of inflammation, and presence of complications. In this article, we will discuss the basic con-
cepts of UC and CD as well as up-to-date information on medical treatment strategies in Japan.
Key Words: inflammatory bowel disease, anti-TNF antibody agent, anti-IL-12/23p40 antibody agent, anti-
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Figure　1　Definition of IBD. 
Broadly, IBD refers to all diseases which cause inflammation of the intestines, but in par-
ticular, UC and CD.






















































Figure　2　Endoscopic findings of UC.
The typical endoscopic findings of UC are diffuse, continuous, and generalized inflamma-
tory images. Inflammation extends continuously from the rectum to the mouth side, and a 
border of inflamed mucosa can be observed. Moreover, diffuse inflammation is observed in 
the mucosa surrounding the ulcer (intervening mucosa). Inflammatory polyps, which are 
remnants of inflammation, may be found in the healing mucosa. A lesion at the appendiceal 
orifice is a suspicious finding for UC, even if a rectal lesion is mild and difficult to detect. 
UC, ulcerative colitis.
Figure　3　Endoscopic findings and effective treatment for CD.
Case of a man with CD in his 20s. Infliximab was introduced early during diagnosis and 
mucosal healing was achieved after 6 months. Left: longitudinal ulceration in the ileum. 


















Genome Wide Asscociation Study（GWAS）解析に
よって多くの疾患感受性遺伝子が報告されている３）．
UCでは human leukocyte antigen（HLA），CDでは
欧 米 で は nucleotide-binding oligomerization
domain-containing protein 2（NOD2）４），日本人を含
むアジア人種においては TNF superfamily member
15（TNFSF15）などが注目され５），また両疾患におい
て interleukin（IL）-23R，IL-12B，signal transclucer












細胞と Th17細胞，CDは Th1細胞と Th17細胞と
いった炎症性 T細胞と炎症を抑制する働きを有す






















































Figure　4　Inflammatory cells and cytokine networks in IBD.
Abnormalities in innate and acquired immunity caused by the complex interaction of 
genetic factors, dietary factors, and intestinal microbiota are crucial to the pathogenesis 
of IBD. In addition to Th1 and Th2 cells, Th17, Th22, and Treg cells are involved in the 
pathogenesis of IBD. Several drugs targeting the cytokine network formed by these cells 
have been developed.
IBD, inflammatory bowel disease; GATA, GATA-binding protein; IL, interleukin; IFN, in-
terferon; RORγt, retinoic acid receptor-related orphan receptor-γt; TGFβ，transforming 

































Table　1　Guidelines for the treatment of UC in Japan. (Adapted from reference 1)
Treatment guidelines for ulcerative colitis suggest treatment options based on the extent and degree of inflammation. Furthermore, 




















脱毛は 6TGNの代謝酵素である nudix hydrolase 15
（NUDT15）の酵素活性が極めて低くなる codon139
における遺伝子多型の存在と関連することが明らか















Table　2　Guidelines for the treatment of CD in Japan. (Adapted from reference 1)
Treatment guidelines for Crohn’s disease suggest treatment options that take into account not only the activity, but also the pres-









































Figure　5　Small molecule drugs for IBD.
Small-molecule drugs used for the treatment of IBD in-
clude classic steroids and immunomodulators such as 
cyclosporine, tacrolimus, and azathioprine. Recently, JAK 
inhibitors, which inhibit JAK-STAT signaling, have also
been used for UC.
IBD, inflammatory bowel disease; JAK, Janus kinase; 
STAT, signal transducer and activator of transcription;
UC, ulcerative colitis.
Table　3　Susceptibility to thiopurine associated with the NUDT15 genotype.




Risk of side effects when starting at a normal dose Starting amount 
considered safeAcute severe leukopenia Whole hair loss
Arg/Arg 81.1% Extremely rare (<0.1%) Extremely rare (<0.1%) AZA 50 mg/day
6-MP 30 mg/day
Arg/His
Arg/Cys 17.8% Low (<5%) Low (<5%) AZA 25 mg/day
6-MP 10-15 mg/day
Cys/His <0.05% High (>50%) High (<5%) 6-MP 5-10 mg/day
Cys/Cys 1.1% Inevitable occurrence Inevitable occurrence Prohibited
For patients being considered for thiopurine therapy, it is recommended that this test be performed prior to initiating 
treatment with thiopurines to confirm the NUDT15 genotype and determine the indication for thiopurines.
















における CDの効果減弱例では 10 mg/kgの倍量投
与もしくは 4週間ごとの期間短縮投与ができる．
ADAは初回 160 mgの皮下注射を行い，2週間後に
80 mgの皮下注射を行う．その後は 40 mgの皮下注
射を 2週間ごとに寛解維持療法として行う．維持療
























Table　4　Major Cytokines Involved 
in Inflammatory Bowel Disease and 
JAK complex against cytokines in-


















JAK is composed of four different 
molecules, JAK1, JAK2, JAK3, and 
tyrosine kinase (TYK2), whose cy-
tokine signaling is specifically de-
termined by the combination with 
STAT.
IL, interleukin; IFN, interferon; 




































































Figure　6　Approval of biologics for UC and CD in Japan.
Since the use of infliximab for CD began in 2002, the same TNF inhibitors have mainly 
been used for this purpose. In recent years, drugs with new mechanisms of action, such as 
IL12/23p40 antibodies and integrin inhibitors, have been launched. Notably, the available 
dosing options vary by disease.
CD, crohn’s disease; IFX, infliximab; ADA, adalimumab; BS, biosimilar; GLM, golimumab; 
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